|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
21 July 2016 |
|
Main ID: |
NCT02410759 |
|
Date of registration:
|
31/03/2015 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally
|
|
Scientific title:
|
Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial |
|
Date of first enrolment:
|
April 2015 |
|
Target sample size:
|
200 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT02410759 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
|
|
Phase:
|
Phase 3
|
|
|
Countries of recruitment
|
|
Egypt
| | | | | | | |
|
Contacts
|
|
Name:
|
AbdelGany MA Hassan, MRCOG, MD |
|
Address:
|
|
|
Telephone:
|
+201017801604 |
|
Email:
|
abdelgany2@gmail.com |
|
Affiliation:
|
|
|
|
Name:
|
AbdelGany M Hassan |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Cairo University |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Women with atonic PPH.
Exclusion Criteria:
- Gestational age <37 weeks.
- Hypertension.
- Preeclampsia.
- Cardiac, renal or liver diseases
- Epilepsy.
- Known hypersensitivity to Carbetocin
Age minimum:
20 Years
Age maximum:
40 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Post Partum Hemorrhage
|
|
Intervention(s)
|
|
Drug: Ergometrine
|
|
Drug: Carbetocin
|
|
Primary Outcome(s)
|
|
Need for other uterotonics
[Time Frame: 2 minutes after giving the drug.]
|
|
Secondary Outcome(s)
|
|
Development of major PPH
[Time Frame: 10 minutes after giving the drug]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|